FLIR Wins U.S. Army Heavyweight Robot Contract Worth Up to $109M
4.12.2019 16:00:00 EET | Business Wire | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) announced that its Kobra™ robot has been chosen for the United States (U.S.) Army’s Common Robotic System-Heavy (CRS-H) program. The five-year production contract to build upwards of 350 unmanned ground vehicles (UGVs) is worth up to $109 million.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191204005221/en/
The U.S. Army has chosen the FLIR Kobra™ robot for its Common Robotic System-Heavy (CRS-H) program. Soldiers will use the robot to perform a range of tasks, such as disarming vehicle-borne improvised explosive devices or other dangerous heavy-duty missions. (Photo: Business Wire)
The CRS-H program will give the Army a ‘program of record’ to build and sustain a fleet of large UGVs for years to come. The CRS-H platform calls for a robot weighing up to 700 pounds. Army Explosive Ordnance Disposal (EOD) units will use the system to perform a range of missions, such as disarming vehicle-borne improvised explosive devices (VBIEDs), unexploded ordnance, or related heavy-duty tasks. A variety of sensors and payloads also can be added to the UGV to support other missions.
“We are pleased to be selected for the U.S. Army’s CRS-H program and deliver lifesaving robotic technology to our soldiers,” said Jim Cannon, president and CEO at FLIR. “This award exemplifies why we acquired Endeavor Robotics earlier this year — to capture strategic programs of record that enable us to integrate advanced solutions for the warfighter, give us the fuel to grow our business, and strengthen our position as a leader in unmanned systems.”
Over several months and two rounds of testing, the Army compared the FLIR Kobra with other vendor systems. Entrants were evaluated on robot reliability, maneuverability, and usability, among other factors before Kobra was selected as the winner. Previously, in 2017 the Army chose FLIR’s legacy business, Endeavor Robotics, as its medium-sized UGV provider through the Man Transportable Robotic System Increment II (MTRS Inc II) contract. FLIR is delivering its Centaur™ UGV under this on-going program.
“Our CRS-H platform will give soldiers a powerful, extremely mobile, yet highly transportable UGV, ready to deploy at a moment’s notice to keep them out of harm’s way,” said David Ray, president of the Government and Defense Business Unit at FLIR. “This win is a testament to our employees who’ve designed such an advanced, multi-mission UGV. We look forward to working with the Army to get this robot into the field and deployed with our warfighters.”
FLIR Kobra delivers unmatched strength, power, and payload support in an easy-to-operate robot package. Kobra has a lift capacity of 330 lbs. (150 kg.) and can stretch up to eleven-and-a-half feet to access hard-to-reach places. Ready for indoor and outdoor use, Kobra maintains mobility on tough terrain and can overcome obstacles such as jersey barriers.
The award covers a five-year production period with shipments beginning in the second quarter of 2020.
For more on FLIR Systems’ Unmanned Ground Systems platforms, visit www.flir.com/UIS/UGS.
About FLIR Systems, Inc.
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense, industrial, and commercial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense,” creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
Forward Looking Statements
The statements in this release by Jim Cannon and David Ray and the other statements in this release about the contract and order described above are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based on current expectations, estimates, and projections about FLIR's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including the following: the ability to manufacture and deliver the systems referenced in this release, changes in pricing of FLIR's products, changing demand for FLIR's products, product mix, the impact of competitive products and pricing, constraints on supplies of critical components, excess or shortage of production capacity, the ability of FLIR to manufacture and ship products in a timely manner, FLIR's continuing compliance with U.S. export control laws and regulations, and other risks discussed from time to time in FLIR's Securities and Exchange Commission filings and reports. In addition, such statements could be affected by general industry and market conditions and growth rates, and general domestic and international economic conditions. Such forward-looking statements speak only as of the date on which they are made and FLIR does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release, or for changes made to this document by wire services or Internet service providers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191204005221/en/
Contact information
Media Contact:
Joe Ailinger
Phone: 978-769-9339; 781-801-6161
Email: joe.ailinger@flir.com
Investor Relations:
Lasse Glassen
Addo Investor Relations
Phone: 424-238-6249
Email: lglassen@addoir.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom